8-K: Cardio Diagnostics Faces Nasdaq Delisting Threat After Share Price Falls Below $1.00

Cardio Diagnostics Holdings, Inc. has received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock price has remained below $1.00 for 30 consecutive business days.

Summary

• Cardio Diagnostics Holdings, Inc. received a notice from Nasdaq on June 3, 2024, stating that they are not in compliance with the minimum bid price rule.
• The company's stock price has been below $1.00 per share for 30 consecutive business days, triggering the non-compliance notice.
• Cardio Diagnostics has until December 2, 2024, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If the company fails to meet this requirement by the deadline, they may be eligible for an additional 180-day compliance period, subject to meeting other listing requirements.
• Failure to regain compliance could lead to the delisting of the company's common stock from the Nasdaq Capital Market.
• The company is considering options to regain compliance, including a potential reverse stock split.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (potential delisting) and uncertainty about the company's ability to recover, leading to a low sentiment score.

Positives

• The company has been given a 180-day period to regain compliance with the minimum bid price rule.
• There is a possibility of an additional 180-day compliance period if certain conditions are met.
• The company is actively exploring options to regain compliance, including a reverse stock split.

Negatives

• The company's stock price has been below $1.00 for 30 consecutive business days, triggering the non-compliance notice.
• There is a risk of delisting from the Nasdaq Capital Market if compliance is not regained.
• The company's stock price is currently not meeting the minimum bid price requirement.

Risks

• There is no guarantee that the company will regain compliance with the minimum bid price requirement within the given timeframe.
• The company may not be eligible for an additional 180-day compliance period.
• A reverse stock split may negatively impact the stock price.
• Delisting from Nasdaq could negatively impact the company's ability to raise capital and its overall valuation.

Future Outlook

The company intends to actively monitor its stock price and consider all available options, including a reverse stock split, to regain compliance with Nasdaq's minimum bid price requirement, but there is no assurance of success.

Management Comments

• The company intends to actively monitor the closing bid price of its common stock.
• The company will consider all available options to regain compliance with the minimum bid price requirement, which may include effecting a reverse stock split.

Industry Context

This announcement reflects a common challenge faced by companies listed on exchanges like Nasdaq, where maintaining a minimum share price is crucial for continued listing. Many companies in the biotech and healthcare sectors, especially those in early stages, can experience share price volatility that leads to such compliance issues.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining minimum bid prices on exchanges like Nasdaq.
• Companies like Athersys and Ocugen have also faced delisting notices due to low share prices, highlighting the commonality of this issue in the sector.
• A reverse stock split is a common strategy used by companies in this situation, but its effectiveness varies and can sometimes negatively impact investor sentiment.
• The 180-day compliance period is a standard procedure provided by Nasdaq to allow companies time to rectify the issue.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decrease in the value of their investment.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may have concerns about the company's long-term viability.

Next Steps

• The company will monitor its stock price.
• The company will consider options to regain compliance, including a reverse stock split.
• The company will attempt to have its stock price close at or above $1.00 for at least ten consecutive business days before December 2, 2024.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, reverse stock split, CDIO, stock price